How do you choose the right DPP-4 inhibitor for your patients with type 2 diabetes?
SAVOR: The Onglyza CV outcomes study
SAVOR included a broad range of diabetes patients1
The 16,492 highly comorbid patients on the SAVOR study had a history of documented T2D, an HbA1c level of 6.5-12.0% and either a history of established cardiovascular disease or multiple risk factors of vascular disease1
1. Scirica BM et al. N Engl J Med 2013; 369: 1317-1326.